Want to see SE:PILA full AI Analyst Report?
PILA PHARMA AB (PILA) AI Stock Analysis
PILA PHARMA AB
(Nasdaq OMX AB:PILA)
The overall score is driven primarily by very weak financial performance, including sharply lower revenue, persistently large losses, and accelerating negative cash flow that heighten funding and dilution risk despite a clean, debt-free balance sheet and recapitalised equity base. Secondary support comes from neutral-to-positive technical signals, with the share trading above its medium- and long-term moving averages, mildly positive momentum, and low volatility, while valuation remains modest due to a negative P/E and lack of dividend, underscoring the stock’s high dependence on future development milestones rather than current fundamentals.
PILA PHARMA AB (PILA) vs. iShares MSCI Sweden ETF (EWD)
- Market Cap
- SEK 71.26M
- Dividend Yield
- ―
- Average Volume (3M)
- 81.57K
- Price to Earnings (P/E)
- -3.5
- Beta (1Y)
- 0.16
- Revenue Growth
- -71.19%
- EPS Growth
- -23.18%
- Country
- Sweden
- Employees
- 1
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
PILA PHARMA AB Business Overview & Revenue Model
Company Description
Based in Sweden, PILA PHARMA AB (publ) is a pharmaceutical firm actively engaged in clinical development. The company's principal drug, XEN-D0501, is a TRPV1 antagonist which has successfully completed two phase 2a clinical studies aimed at treating...
How the Company Makes Money
As a clinical-stage pharmaceutical company, PILA PHARMA AB’s ability to generate recurring commercial revenue depends on successful drug development and subsequent commercialization or partnering. Specific, company-reported details on current revenue...
PILA PHARMA AB Financial Statement Overview
Summary
Financial performance is weak, with sharply lower TTM revenue versus 2025, persistent large operating and net losses, and deeply negative operating and free cash flow, partially offset by a debt-free balance sheet and recapitalised equity base that provides some funding runway.
Income Statement
23NegativeBalance Sheet
57NeutralCash Flow
19Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 275.74K | 1.13M | 775.00K | 1.46M | 1.88M | 719.23K |
| Gross Profit | -5.95M | -6.82M | -8.12M | 1.46M | 1.88M | 680.94K |
| EBITDA | -6.71M | -15.92M | -10.11M | -8.81M | -26.76M | -17.16M |
| Net Income | -16.77M | -16.86M | -11.24M | -9.93M | -26.78M | -17.21M |
Balance Sheet | ||||||
| Total Assets | 16.86M | 16.22M | 6.22M | 8.46M | 10.89M | 31.81M |
| Cash, Cash Equivalents and Short-Term Investments | 3.26M | 15.90M | 4.89M | 5.95M | 7.24M | 28.21M |
| Total Debt | 0 | 0 | 0 | 773.08K | 0 | 0 |
| Total Liabilities | 748.00K | 1.43M | 963.00K | 1.79M | 1.36M | 1.51M |
| Stockholders Equity | 16.11M | 14.78M | 5.26M | 6.66M | 9.53M | 30.30M |
Cash Flow | ||||||
| Free Cash Flow | -20.79M | -9.19M | -7.82M | -4.85M | -9.09M | -9.36M |
| Operating Cash Flow | -20.79M | -9.19M | -7.82M | -4.85M | -9.09M | -9.36M |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 22.97M | 20.19M | 6.76M | 3.56M | -11.88M | 35.67M |
PILA PHARMA AB Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:PILA, the sentiment is Negative. The current price of 1.41 is below the 20-day moving average (MA) of 1.59, below the 50-day MA of 1.71, and below the 200-day MA of 1.51, indicating a bearish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 39.72 is Neutral, neither overbought nor oversold. The STOCH value of 61.85 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:PILA.
PILA PHARMA AB Peers Comparison
Overall Rating
- SE:PILA48Neutral
SE:ACE44Neutral
SE:ONCOZ40Underperform
SE:MODTX39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| SE:PILA | 48Neutral | SEK 71.26M | -3.47 | -108.78% | ― | -71.19% | -23.18% |
| SE:ACE | 44Neutral | SEK 77.45M | -1.15 | -62.21% | ― | ― | 58.15% |
| SE:ONCOZ | 40Underperform | SEK 85.84M | -1.62 | -2775.09% | ― | 115.26% | -230.43% |
| SE:MODTX | 39Underperform | SEK 31.19M | -0.90 | -177.45% | ― | ― | 0.22% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SE:PILA | PILA PHARMA AB | 1.41 | -0.76 | -35.02% | |
| SE:ONCOZ | OncoZenge AB | 3.10 | -1.27 | -29.11% | |
| SE:ACE | Ascelia Pharma AB | 0.56 | -2.52 | -81.95% | |
| SE:MODTX | Modus Therapeutics Holding AB | 0.16 | -0.23 | -58.52% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 24, 2026